These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32637957)

  • 1. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
    Chiuppesi F; Salazar MD; Contreras H; Nguyen VH; Martinez J; Park S; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt ND; Kang TH; Wu X; Rogers T; Manuel ER; Shostak Y; Diamond DJ; Wussow F
    bioRxiv; 2020 Jul; ():. PubMed ID: 32637957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
    Chiuppesi F; Salazar MD; Contreras H; Nguyen V; Martinez J; Park S; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt N; Kang T; Wu X; Rogers T; Manuel E; Shostak Y; Diamond D; Wussow F
    Res Sq; 2020 Jul; ():. PubMed ID: 32702732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
    Chiuppesi F; Salazar MD; Contreras H; Nguyen VH; Martinez J; Park Y; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt ND; Kang TH; Wu X; Rogers TF; Manuel ER; Shostak Y; Diamond DJ; Wussow F
    Nat Commun; 2020 Nov; 11(1):6121. PubMed ID: 33257686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
    García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
    Chiuppesi F; Zaia JA; Gutierrez-Franco MA; Ortega-Francisco S; Ly M; Kha M; Kim T; Dempsey S; Kar S; Grifoni A; Sette A; Wussow F; Diamond DJ
    Commun Med (Lond); 2024 Feb; 4(1):19. PubMed ID: 38366141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
    Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE
    Front Immunol; 2023; 14():1160065. PubMed ID: 37404819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
    Kalodimou G; Jany S; Freudenstein A; Schwarz JH; Limpinsel L; Rohde C; Kupke A; Becker S; Volz A; Tscherne A; Sutter G
    Viruses; 2023 May; 15(5):. PubMed ID: 37243266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jun; ():e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.
    Lorenzo MM; Marín-López A; Chiem K; Jimenez-Cabello L; Ullah I; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Moreno S; Ye C; Park JG; Matía A; Brun A; Sánchez-Puig JM; Nogales A; Mothes W; Uchil PD; Kumar P; Ortego J; Fikrig E; Martinez-Sobrido L; Blasco R
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
    Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
    Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.
    Mooij P; García-Arriaza J; Pérez P; Lázaro-Frías A; Verstrepen BE; Böszörményi KP; Mortier D; Fagrouch Z; Kiemenyi-Kayere G; Niphuis H; Acar RF; Meijer L; Stammes MA; Kondova I; Verschoor EJ; GeurtsvanKessel CH; de Bruin E; Sikkema RS; Luczkowiak J; Delgado R; Montenegro D; Puentes E; Rodríguez E; Bogers WMJM; Koopman G; Esteban M
    Front Immunol; 2022; 13():845887. PubMed ID: 35371043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.